Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy.

Autor: Liu Y; Department of Ophthalmology, Eye and ENT Hospital of Fudan University, No.83, Fen Yang Road, Shanghai, 200031, China.; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, China.; Key Laboratory of Myopia of State Health Ministry, Fudan University, Shanghai, China., Guo J; Department of Ophthalmology, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Tang W; Department of Ophthalmology, Eye and ENT Hospital of Fudan University, No.83, Fen Yang Road, Shanghai, 200031, China.; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, China.; Key Laboratory of Myopia of State Health Ministry, Fudan University, Shanghai, China., Xu G; Department of Ophthalmology, Eye and ENT Hospital of Fudan University, No.83, Fen Yang Road, Shanghai, 200031, China.; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, China.; Key Laboratory of Myopia of State Health Ministry, Fudan University, Shanghai, China., Liu W; Department of Ophthalmology, Eye and ENT Hospital of Fudan University, No.83, Fen Yang Road, Shanghai, 200031, China. Bfgf2020@163.com.; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, China. Bfgf2020@163.com.; Key Laboratory of Myopia of State Health Ministry, Fudan University, Shanghai, China. Bfgf2020@163.com.
Jazyk: angličtina
Zdroj: BMC ophthalmology [BMC Ophthalmol] 2024 Oct 08; Vol. 24 (1), pp. 441. Date of Electronic Publication: 2024 Oct 08.
DOI: 10.1186/s12886-024-03687-0
Abstrakt: Background: This study aims to evaluate the two-year outcomes of polypoidal choroidal vasculopathy (PCV) treated with conbercept and to investigate the predictive response factors.
Methods: Consecutive patients with PCV who received three-loading intravitreal conbercept, followed by as-needed reinjections, were studied retrospectively. The best corrected visual acuity (BCVA), central retinal thickness (CRT) and polyps were evaluated. Patients who achieved dry maculae in month 6 were categorised into the dry group, or otherwise, into the non-dry group. The predictive factors for a dry macula were evaluated.
Results: A total of 25 eyes from 25 patients (17 males; mean age: 62.8 ± 6.4 years) were included. At month 24, the average BCVA increased significantly from 49.9 ± 15.0 letters to 57.2 ± 16.0 letters (p = 0.040); the average CRT decreased significantly from 430.16 ± 166.55 μm to 278.31 ± 157.34 μm (p = 0.00), and 88% of the eyes achieved dry maculae. The number of polyps changed from 55 to 20 (fading rate: 63.6%; p < 0.001). The mean number of intravitreal injections was 8.6 ± 5.4. The dry group (10 eyes, 40%) was more likely to have higher branching vascular network vessel density (BVN VD; p = 0.021), submacular haemorrhages (p = 0.011) but lack polyp-related serous pigmented epithelial detachment (PED) (p = 0.037).
Conclusions: Conbercept was effective in eyes with PCV at maintaining functional and anatomical improvement. Baseline characteristics, including BVN VD, the presence of polyps with serous PED and submacular haemorrhage, seemed to be related to the response to conbercept.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: